Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

The blood–brain barrier (BBB) restricts the transport of potential therapeutic moieties to the
brain. Direct targeting the brain via olfactory and trigeminal neural pathways by passing the …

Abstract Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's
disease (AD) but its inherent instability limits bioavailability and effectiveness. We found that …

Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

The central nervous system, one of the most delicate microenvironments of the body, is
protected by the blood‐brain barrier (BBB) regulating its homeostasis. BBB is a highly …

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are
caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's …

Alzheimer's disease (AD) is a neurodegenerative disease with high prevalence in the
rapidly growing elderly population in the developing world. The currently FDA approved …

As a progressive, irreversible neurodegenerative disease, Alzheimer's disease (AD)
continues to be a serious public health problem worldwide. Currently, the most available …

The discovery of effective drugs for the treatment of neurodegenerative disorders (NDs) is a
deadlock. Due to their complex etiology and high heterogeneity, progresses in the …

Alzheimer's disease (AD) is characterized by cognitive inability manifested due to the
accumulation of β-amyloid, formation of hyper phosphorylated neurofibrillary tangles, and a …